Orphan drug boom comes with a steady stream of outsourcing
With the FDA approving a record number of orphan drugs in 2014, sponsors weren’t the only ones to reap profits from their development.
Archives for February 17, 2015
Crown Bioscience nabs PDX models, service ops of Molecular Response
Preclinical CRO Crown is acquiring all of Molecular Response’s existing PDX (patient-derived xenograft) models as well as 8,000 viable human tumors for model development.
Targeting stem cell cilia could prevent obesity and yield new cancer and arthritis drugs say researchers
Having shorter hair stops you becoming fat…at least it does if you are a stem cell say researchers who claim restricting the growth of hair-like cilia found on such cells could yield new treatments for obesity.
Fresenius Kabi sells cancer compounding biz to NewCo Pharma
Fresenius Kabi has sold its cancer drug pharmacy network CFL GmbH to NewCo Pharma GmbH five years after spending €42m to buy compounding capacity in Germany.